Want to see RHHBY full AI Analyst Report?
RHHBY Stock Chart & Stats
$54.70
$0.29(0.53%)
At close: 4:00 PM EDT
$54.70
$0.29(0.53%)
Day’s Range― - ―
52-Week Range$37.51 - $60.85
Previous CloseN/A
Volume747.71K
Average Volume (3M)1.83M
Market Cap
$358.16B
Enterprise Value$363.86K
Total Cash (Recent Filing)$9.70B
Total Debt (Recent Filing)$31.69B
Price to Earnings (P/E)24.0
Beta0.38
Next Earnings
Feb 04, 2027EPS Estimate
1.55Next Dividend Ex-DateN/A
Dividend Yield2.8%
Share Statistics
EPS (TTM)1.94
Shares Outstanding5,620,501,500
10 Day Avg. Volume2,128,806
30 Day Avg. Volume1,826,636
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)7.76
Price to Sales (P/S)4.15
P/FCF Ratio19.53
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$55.00Price Target Upside0.55% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)3.11
Revenue Forecast (FY)$77.85B
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsEarly trontinemab data shows competitive amyloid clearance and improved ARIA rate versus peers, but clinical outcomes will determine success.
Financial PerformanceRoche's model was updated and numbers raised post recent business trends, with sales and EPS growth estimates increased.
Product EfficacyGazyva showed potential best-in-class profile in lupus nephritis and is likely to be the starter therapy of choice versus GSK's Benlysta.
Bears Say
Clinical Trial SafetyThere was a case of fatal cerebral macrohemorrhage in Part 2, leading to updated trial criteria to exclude patients with superficial siderosis.
Placebo ResponseThe high placebo response rate in males was notable, where placebo achieved a 66.7% complete renal response compared to 42.9% for Gazyva.
Roche Holding News
RHHBY FAQ
What was Roche Holding AG’s price range in the past 12 months?
Roche Holding AG lowest stock price was $37.51 and its highest was $60.85 in the past 12 months.
What is Roche Holding AG’s market cap?
Roche Holding AG’s market cap is $358.16B.
When is Roche Holding AG’s upcoming earnings report date?
Roche Holding AG’s upcoming earnings report date is Feb 04, 2027 which is in 188 days.
How were Roche Holding AG’s earnings last quarter?
Roche Holding AG released its earnings results on Jul 23, 2026. The company reported $1.661 earnings per share for the quarter, beating the consensus estimate of $1.601 by $0.06.
Is Roche Holding AG overvalued?
According to Wall Street analysts Roche Holding AG’s price is currently Undervalued.
Does Roche Holding AG pay dividends?
Roche Holding AG pays a Annually dividend of $1.55 which represents an annual dividend yield of 2.8%. See more information on Roche Holding AG dividends here
What is Roche Holding AG’s EPS estimate?
Roche Holding AG’s EPS estimate is 1.55.
How many shares outstanding does Roche Holding AG have?
Roche Holding AG has 5,620,501,500 shares outstanding.
What happened to Roche Holding AG’s price movement after its last earnings report?
Roche Holding AG reported an EPS of $1.661 in its last earnings report, beating expectations of $1.601. Following the earnings report the stock price went up 4.294%.
Which hedge fund is a major shareholder of Roche Holding AG?
Currently, no hedge funds are holding shares in RHHBY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Roche Holding Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$55.00 (0.55% Upside)
$55.00 (0.55% Upside)
Blogger Sentiment
Bullish
RHHBY Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
2.80%
Trailing 12-Months
Asset Growth
2.26%
Trailing 12-Months
Company Description
Roche Holding AG
Roche Holding AG (RHHBY) is a Switzerland-based global healthcare company operating primarily through two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals division develops and markets prescription medicines, including specialty therapies in areas such as oncology, immunology, neuroscience, infectious diseases, and ophthalmology. The Diagnostics division provides in vitro diagnostic systems, tests, instruments, and related services used by hospitals, laboratories, and blood banks, spanning areas such as molecular diagnostics, immunoassays, pathology, and diabetes care.
RHHBY Company Deck
RHHBY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed a positive operating and pipeline momentum despite identifiable headwinds. Roche reported strong profitability (core op profit +10%, margin expansion), solid organic growth in Pharma, multiple regulatory wins (5 priority reviews) and major diagnostics and R&D milestones (AXELIOS launch, CE marks, strategic M&A). Offsetting items include China pricing reform and a weak respiratory season hitting Diagnostics, currency translation pressures, a near‑term net debt increase (timing effects) and some competitive/biosimilar pressure in specific franchises. On balance, the operational and pipeline achievements materially outweigh the manageable challenges described.View all RHHBY earnings summariesRHHBY Stock 12 Month Forecast
Average Price Target
$55.00
▲(0.55% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.54% Mutual Funds
0.03% Other Institutional Investors
99.39% Public Companies and
Individual Investors